王大力,孫正芹,敦昌平,顧平
·論著·
帕金森病焦慮與運(yùn)動(dòng)并發(fā)癥關(guān)系的研究
王大力,孫正芹,敦昌平,顧平
目的探討帕金森病(PD)焦慮與運(yùn)動(dòng)并發(fā)癥的關(guān)系。方法收集82例PD患者的病史資料,采用漢密爾頓焦慮量表14項(xiàng)版本(HAMA14)、漢密爾頓抑郁量表24項(xiàng)版本(HAMD24)、蒙特利爾認(rèn)知評(píng)估量表(MoCA)、統(tǒng)一PD評(píng)定量表第Ⅲ部分(UPDRS Ⅲ)、統(tǒng)一PD評(píng)定量表第Ⅳ部分(UPDRS Ⅳ)及Hoehn-Yahr分期對(duì)PD患者進(jìn)行評(píng)測(cè),分析PD焦慮與運(yùn)動(dòng)并發(fā)癥之間的關(guān)系。結(jié)果82例PD患者焦慮的發(fā)生率為47.56%,運(yùn)動(dòng)并發(fā)癥的發(fā)生率為43.90%。與非焦慮組比較,焦慮組患者運(yùn)動(dòng)并發(fā)癥、“開(kāi)-關(guān)”現(xiàn)象的發(fā)生率以及HAMD24評(píng)分、UPDRS Ⅲ評(píng)分、Hoehn-Yahr分期明顯增高,病程明顯延長(zhǎng),MoCA評(píng)分明顯降低(均P<0.05)。多元回歸分析顯示,PD患者HAMD24評(píng)分、Hoehn-Yahr分期與HAMA14評(píng)分呈正相關(guān)(均P<0.05)。多因素Logistic回歸分析顯示,Hoehn-Yahr分期為PD運(yùn)動(dòng)并發(fā)癥的獨(dú)立影響因素(OR=2.462,P<0.05)。結(jié)論P(yáng)D焦慮的患者運(yùn)動(dòng)并發(fā)癥的發(fā)生率高,且容易出現(xiàn)“開(kāi)-關(guān)”現(xiàn)象。抑郁評(píng)分越高、病情越重,越容易產(chǎn)生焦慮。
帕金森??;焦慮;運(yùn)動(dòng)并發(fā)癥
帕金森病(PD)是一種運(yùn)動(dòng)癥狀與非運(yùn)動(dòng)癥狀并存的神經(jīng)系統(tǒng)退行性疾病。 PD患者常伴有焦慮、抑郁、便秘、嗅覺(jué)減退、快速動(dòng)眼睡眠行為異常、自主神經(jīng)功能紊亂等非運(yùn)動(dòng)癥狀。有研究[1-3]發(fā)現(xiàn),焦慮作為常見(jiàn)的PD非運(yùn)動(dòng)癥狀之一,其患病率可高達(dá)50%。但在臨床工作中,PD焦慮通常易于忽視,而焦慮情緒是降低PD患者生活質(zhì)量、加重家庭及社會(huì)負(fù)擔(dān)的主要原因[4]。本研究探討焦慮與PD患者運(yùn)動(dòng)并發(fā)癥之間的關(guān)聯(lián),為PD運(yùn)動(dòng)并發(fā)癥的診治提供臨床依據(jù)。
1.1 對(duì)象 連續(xù)收集2015年7月~2016年7月于河北醫(yī)科大學(xué)第一醫(yī)院就診的PD患者82例,其中男34例,女48例;年齡39~87歲,平均(66.8±9.2)歲;發(fā)病年齡32歲~80歲,平均(61.0±9.8)歲;病程0.5~19年,中位數(shù)5年。所有研究對(duì)象均符合英國(guó)腦庫(kù)原發(fā)性PD診斷標(biāo)準(zhǔn),并排除以下患者:(1)正在服用抗焦慮藥物的患者;(2)原發(fā)性震顫;(3)藥物、中毒、腦炎、腦血管病、腦外傷等各種原因所致的帕金森綜合征;(4)多系統(tǒng)萎縮、皮質(zhì)基底節(jié)變性、進(jìn)行性核上性眼肌麻痹等帕金森疊加綜合征;(5)嚴(yán)重認(rèn)知功能障礙、腫瘤及其他精神疾病的患者。
1.2 方法
1.2.1 臨床資料采集及量表評(píng)估 所有PD患者均由專(zhuān)科醫(yī)師對(duì)其進(jìn)行統(tǒng)一臨床資料采集及量表評(píng)估,采用漢密爾頓焦慮量表14項(xiàng)版本(HAMA14)對(duì)患者進(jìn)行焦慮評(píng)測(cè),將HAMA14評(píng)分≥14分定義為焦慮組,HAMA14評(píng)分<14分定義為非焦慮組。采用漢密爾頓抑郁量表24項(xiàng)版本(HAMD24)對(duì)PD患者進(jìn)行抑郁評(píng)測(cè),采用蒙特利爾認(rèn)知評(píng)估量表(MoCA)對(duì)PD患者進(jìn)行認(rèn)知功能評(píng)測(cè)。采用統(tǒng)一PD評(píng)定量表第Ⅲ部分(UPDRS Ⅲ)及Hoehn-Yahr分期評(píng)測(cè)患者運(yùn)動(dòng)功能。采用統(tǒng)一PD評(píng)定量表第Ⅳ部分(UPDRS Ⅳ)評(píng)測(cè)患者運(yùn)動(dòng)并發(fā)癥,其中第32~35項(xiàng)總分≥1分定義為存在異動(dòng)癥,第36項(xiàng)=1分定義為存在劑末現(xiàn)象,第37項(xiàng)與38項(xiàng)總分=2分定義為存在“開(kāi)-關(guān)”現(xiàn)象。
2.1 臨床資料采集結(jié)果及分組 82例PD患者HAMD24評(píng)分1~31分,平均(13.7±6.1)分;HAMA14評(píng)分3~35分,中位數(shù)13分;MoCA評(píng)分7~30分,中位數(shù)21分;UPDRS Ⅲ評(píng)分0~63分,中位數(shù)23分;Hoehn-Yahr分期1~5級(jí),中位數(shù)2級(jí)。82例PD患者中,36例(43.90%)存在運(yùn)動(dòng)并發(fā)癥,其中33例(40.24%)存在劑末現(xiàn)象,23例(28.05%)存在“開(kāi)-關(guān)”現(xiàn)象,16例(19.51%)存在異動(dòng)癥。根據(jù)HAMA14評(píng)分,82例PD患者分為焦慮組(39例)與非焦慮組(43例),焦慮的發(fā)生率為47.56%。
2.2 PD焦慮組與非焦慮組人口學(xué)特征的比較 見(jiàn)表1。兩組性別、年齡、文化程度等差異無(wú)統(tǒng)計(jì)學(xué)意義(均P>0.05)。
2.3 PD焦慮組與非焦慮組運(yùn)動(dòng)并發(fā)癥的比較 見(jiàn)表2。焦慮組患者運(yùn)動(dòng)并發(fā)癥及“開(kāi)-關(guān)”現(xiàn)象的發(fā)生率均明顯高于非焦慮組(均P<0.05)。兩組劑末現(xiàn)象、異動(dòng)癥發(fā)生率的差異均無(wú)統(tǒng)計(jì)學(xué)意義(均P>0.05)。
2.4 PD焦慮組與非焦慮組其他臨床資料的比較 見(jiàn)表3。與非焦慮組相比,焦慮組病程明顯延長(zhǎng),HAMD24評(píng)分、UPDRS Ⅲ評(píng)分、Hoehn-Yahr分期明顯增高,MoCA評(píng)分明顯降低(均P<0.05)。
表1 PD焦慮組與非焦慮組患者人口學(xué)特征的比較(x±s,例,%)組別例數(shù)年齡(歲)性別男女文化程度小學(xué)及以下中學(xué)大專(zhuān)及以上發(fā)病年齡(歲)焦慮組3967.5±10.412(30.77)27(69.23)12(30.77)20(51.28)7(17.95)59.1±9.8非焦慮組4366.0±9.022(51.16)21(48.84)8(18.60)24(55.81)11(25.58)62.7±9.6P值0.469 0.0610.3940.096
表2 PD焦慮組與非焦慮組患者運(yùn)動(dòng)并發(fā)癥的比較(%)組別例數(shù)運(yùn)動(dòng)并發(fā)癥劑末現(xiàn)象“開(kāi)-關(guān)”現(xiàn)象異動(dòng)癥焦慮組3956.41(22/39)48.72(19/39)38.46(15/39)28.21(11/39)非焦慮組4332.56(14/43)32.56(14/43)18.60(8/43)11.63(5/43)P值0.030.1360.0460.059
表3 PD焦慮組與非焦慮組患者其他臨床資料的比較[Q2(Q1,Q3),x±s]組別例數(shù)病程(年)HAMD24評(píng)分(分)MoCA評(píng)分(分)UPDRSⅢ評(píng)分(分)Hoehn-Yahr分期(期)焦慮組397(4,9)17.7±5.420.5±5.030(17.0,37.0)2.5(1.5,3.0)非焦慮組434(2,7)10.1±4.123.0±4.116(8.0,31.0)2(1.0,2.5)P值0.0070.0000.0160.0210.003
2.5 PD患者HAMA14評(píng)分的影響因素分析 見(jiàn)表4。多元回歸分析顯示,PD患者HAMD24評(píng)分、Hoehn-Yahr分期與HAMA14評(píng)分呈正相關(guān)(均P<0.05)。
表4 PD患者HAMA14評(píng)分的影響因素分析影響因素標(biāo)準(zhǔn)化系數(shù)標(biāo)準(zhǔn)差t值P值病程0.1363.7031.6480.103HAMD24評(píng)分0.6656.0948.8120.000MoCA評(píng)分-0.1024.681-1.3740.173UPDRSⅢ評(píng)分0.06014.6930.5790.564Hoehn-Yahr分期0.2330.9213.0860.003
2.6 PD患者發(fā)生運(yùn)動(dòng)并發(fā)癥的影響因素分析 見(jiàn)表5。多因素Logistic回歸分析顯示,Hoehn-Yahr分期為PD運(yùn)動(dòng)并發(fā)癥的獨(dú)立影響因素(OR=2.462,P<0.05)。
表5 PD患者發(fā)生運(yùn)動(dòng)并發(fā)癥的影響因素分析影響因素運(yùn)動(dòng)并發(fā)癥OR值95%CIP值HAMA14評(píng)分0.9980.885~1.1250.972HAMD24評(píng)分1.0250.910~1.1540.686Hoehn-Yahr分期2.4621.292~4.6930.006
PD是一種由于黑質(zhì)-紋狀體多巴胺能神經(jīng)元缺失導(dǎo)致的神經(jīng)系統(tǒng)退行性疾病。大多數(shù)PD患者經(jīng)過(guò)長(zhǎng)期多巴胺替代治療產(chǎn)生運(yùn)動(dòng)并發(fā)癥,包括癥狀波動(dòng)和異動(dòng)癥。有研究[5]表明,幾乎所有PD伴運(yùn)動(dòng)并發(fā)癥的患者存在非運(yùn)動(dòng)癥狀,如焦慮、抑郁、睡眠障礙、自主神經(jīng)功能紊亂、感覺(jué)異常、認(rèn)知功能下降等。焦慮作為PD重要的非運(yùn)動(dòng)癥狀之一,在PD患者中發(fā)生率為25%~49%[6],本研究PD患者中焦慮的發(fā)生率為47.56%。
雖然目前PD焦慮的產(chǎn)生機(jī)制尚不明確,但總體認(rèn)為與社會(huì)心理因素、腦的病理性損害及治療藥物的影響有關(guān)。Connolly等[7]研究認(rèn)為,PD焦慮的產(chǎn)生可能與社會(huì)心理因素有關(guān),PD運(yùn)動(dòng)癥狀產(chǎn)生的尷尬情感是導(dǎo)致PD焦慮癥狀的主要因素。Simpson等[8]采用疾病感知問(wèn)卷分析其與PD焦慮的關(guān)系,研究表明疾病感知評(píng)分與PD焦慮的產(chǎn)生呈正相關(guān),即患者對(duì)自身疾病的主觀感受越多,越容易產(chǎn)生焦慮,同時(shí)也發(fā)現(xiàn)缺乏社會(huì)支持的PD患者焦慮程度較重。α突觸核蛋白損傷腦部結(jié)構(gòu)及神經(jīng)遞質(zhì)的改變也有可能為PD焦慮產(chǎn)生的機(jī)制之一。Braak等[9]病理學(xué)分期證實(shí)藍(lán)斑及中縫核先于黑質(zhì)致密帶發(fā)生退行性變性,引起腦內(nèi)5-羥色胺、去甲腎上腺素水平的改變。這與PD焦慮癥狀密切相關(guān)[10]。Dissanayaka等[11]認(rèn)為中腦邊緣系統(tǒng)投射至杏仁核的多巴胺能傳導(dǎo)通路為PD焦慮產(chǎn)生與調(diào)節(jié)的關(guān)鍵部位,并且認(rèn)為這些傳導(dǎo)通路的神經(jīng)退行性變與PD焦慮的產(chǎn)生相關(guān)。此外,PD焦慮可能與左旋多巴的替代治療有關(guān)[7]。
PD焦慮與抑郁、運(yùn)動(dòng)功能的嚴(yán)重程度密切相關(guān)。抑郁是PD患者常見(jiàn)的非運(yùn)動(dòng)癥狀,抑郁常與焦慮共患。目前,焦慮抑郁的共病機(jī)制尚不明確。有學(xué)者[12-13]認(rèn)為二者在神經(jīng)生化方面具有同源性。本研究發(fā)現(xiàn),焦慮組抑郁評(píng)分較非焦慮組高,提示焦慮的PD患者更容易罹患抑郁,與劉卓等[13]的研究報(bào)道一致。Qureshi等[14]研究表明,PD抑郁的患者是非抑郁患者共患焦慮的5倍。本研究多元回歸分析亦提示抑郁為焦慮的危險(xiǎn)因素,提示抑郁的患者更容易產(chǎn)生焦慮癥狀,PD焦慮、抑郁在一定程度上相互加劇。Dissanayaka等[3]研究證實(shí),UPDRS Ⅲ評(píng)分高、Hoehn-Yahr分期嚴(yán)重為PD焦慮的危險(xiǎn)因素,提示PD患者運(yùn)動(dòng)功能越差,越容易出現(xiàn)焦慮癥狀。左旋多巴可能通過(guò)改善PD患者的運(yùn)動(dòng)功能而緩解焦慮情緒[15]。本研究發(fā)現(xiàn)焦慮的PD患者有較高的UPDRS Ⅲ評(píng)分、Hoehn-Yahr分期,多元回歸分析提示UPDRS Ⅲ評(píng)分與HAMA14評(píng)分無(wú)明顯相關(guān)性,而Hoehn-Yahr分期與HAMA14評(píng)分呈正相關(guān),可能Hoehn-Yahr分期較UPDRS Ⅲ評(píng)分對(duì)HAMA14評(píng)分的影響更為敏感,更加能夠反映運(yùn)動(dòng)功能的嚴(yán)重程度。由此看來(lái),PD焦慮與運(yùn)動(dòng)功能障礙相互促進(jìn),造成惡性循環(huán)。焦慮與認(rèn)知功能障礙之間的關(guān)系尚存在爭(zhēng)議。劉惠苗等[16]研究發(fā)現(xiàn),存在焦慮的PD患者認(rèn)知功能障礙發(fā)生率較高,PD焦慮癥狀可以誘發(fā)或加重認(rèn)知損害的程度。然而,F(xiàn)onoff等[17]研究發(fā)現(xiàn),焦慮對(duì)PD患者的執(zhí)行功能無(wú)顯著影響。PD焦慮癥狀的出現(xiàn)與5-羥色胺、去甲腎上腺素、多巴胺等神經(jīng)遞質(zhì)的改變有關(guān),而PD認(rèn)知功能障礙主要是乙酰膽堿水平的下降[13]。本研究發(fā)現(xiàn),焦慮的PD患者M(jìn)oCA評(píng)分較低,而多元回歸分析提示MoCA評(píng)分與HAMA14評(píng)分無(wú)明確相關(guān)性,二者之間的關(guān)系有待深入研究。
運(yùn)動(dòng)并發(fā)癥是PD治療過(guò)程中最常見(jiàn)的癥狀,也是藥物治療的難點(diǎn)。Ahlskog等[18]認(rèn)為,PD患者經(jīng)過(guò)4~6年的左旋多巴治療,40%患者產(chǎn)生運(yùn)動(dòng)并發(fā)癥。Bjornestad等[19]前瞻性隊(duì)列研究發(fā)現(xiàn),PD后5年運(yùn)動(dòng)并發(fā)癥的發(fā)生率為52.4%。本研究運(yùn)動(dòng)并發(fā)癥的發(fā)生率為43.90%。運(yùn)動(dòng)并發(fā)癥嚴(yán)重影響PD患者的生活質(zhì)量[20]。目前,焦慮與運(yùn)動(dòng)并發(fā)癥的關(guān)系逐漸受到關(guān)注。有研究[21]發(fā)現(xiàn),大約75%PD患者存在焦慮、癥狀波動(dòng)或二者并存。Marsh等[22]發(fā)現(xiàn)PD運(yùn)動(dòng)并發(fā)癥產(chǎn)生的預(yù)期性焦慮的發(fā)生率為10%。PD劑末現(xiàn)象可引起焦慮,其焦慮癥狀的表現(xiàn)形式不僅僅局限于主觀感覺(jué)性焦慮,還包括軀體性焦慮癥狀,如排汗異常、腹痛、呼吸急促[23]。癥狀波動(dòng)的患者比無(wú)癥狀波動(dòng)的患者更容易產(chǎn)生社交恐懼、驚恐發(fā)作與較高的HAMA14評(píng)分、貝克焦慮量表評(píng)分,且廣泛性焦慮障礙的發(fā)生率是無(wú)癥狀波動(dòng)患者的2倍[24]。有研究[25]評(píng)估PD患者“開(kāi)-關(guān)”期的焦慮情況,結(jié)果表明處于“關(guān)”期的PD患者有較高的焦慮評(píng)分。PD患者存在“開(kāi)-關(guān)”現(xiàn)象的患者與焦慮癥狀的出現(xiàn)呈正相關(guān)[3],而焦慮評(píng)分在PD有無(wú)異動(dòng)癥的患者中無(wú)顯著差異[26]。本研究發(fā)現(xiàn),焦慮組“開(kāi)-關(guān)”現(xiàn)象的發(fā)病率高于非焦慮組,而兩組間劑末現(xiàn)象、異動(dòng)癥之間的差異無(wú)統(tǒng)計(jì)學(xué)意義,原因可能在于與異動(dòng)現(xiàn)象相比,處于“開(kāi)-關(guān)”現(xiàn)象的患者更易產(chǎn)生跌倒恐懼,從而出現(xiàn)各種焦慮癥狀的反應(yīng)。
本研究發(fā)現(xiàn),焦慮的PD患者運(yùn)動(dòng)并發(fā)癥的發(fā)生率高,且焦慮的PD患者容易產(chǎn)生“開(kāi)-關(guān)”現(xiàn)象。與非焦慮的患者相比,焦慮的PD患者病程明顯延長(zhǎng),HAMD24評(píng)分、UPDRS Ⅲ評(píng)分、Hoehn-Yahr分期明顯增高,MoCA評(píng)分降低;而多元回歸分析示,HAMD24評(píng)分、Hoehn-Yahr分期與HAMA14評(píng)分呈正相關(guān),提示抑郁評(píng)分越高、病情越重,越容易產(chǎn)生焦慮。本研究Logistic回歸分析示焦慮不是運(yùn)動(dòng)并發(fā)癥的獨(dú)立危險(xiǎn)因素,原因可能在于疾病的嚴(yán)重程度對(duì)運(yùn)動(dòng)并發(fā)癥的影響更為顯著。本研究未進(jìn)一步研究分析其他非運(yùn)動(dòng)癥狀對(duì)PD患者焦慮的影響,使結(jié)果產(chǎn)生了偏倚。本研究樣本量小,病情較輕,而且只是一橫斷面研究,分析評(píng)價(jià)PD某一階段的狀態(tài),今后需要大樣本的臨床隊(duì)列研究,深入探討焦慮與PD運(yùn)動(dòng)并發(fā)癥的之間的關(guān)聯(lián)。
[1] Leentjens AF,Dujardin K, Marsh L, et al. Anxiety rating scales in Parkinson’s disease: critique and recommendations[J]. Mov Disord, 2008, 23: 2015.
[2] Bower JH, Grossardt BR, Maraganore DM, et al. Anxious personality predicts an increased risk of Parkinson’sdisease[J]. Mov Disord, 2010, 25: 2105.
[3] Dissanayaka NN, Selbach A, Matheson S, et al. Anxiety disordersin Parkinson’s disease: prevalence and risk factors[J]. Mov Disord, 2010, 25: 838.
[4] Marinus J, Leentjens AFG, Visser M, et al. Evaluation of the hospital anxiety and depression scale in patients with Parkinson’s disease[J]. Clin Neuropharmacol, 2002, 25: 318.
[5] Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson’s disease: frequent and disabling[J]. Neurology, 2002, 59: 408.
[6] Pontone GM,Williams JR,Anderson KE, et al. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson’s disease[J]. Mov Disorders, 2009, 24: 1333.
[7] Connolly B, Fox SH. Treatment of cognitive, psychiatric, and affective disordersassociated with Parkinson’s disease[J]. Neurotherapeutics, 2014, 11: 78.
[8] Simpson J, Lekwuwa G, Crawford T. Illness beliefs and psychological outcome in people with Parkinson’s disease[J]. Chronic Illn, 2013, 9: 165.
[9] Braak H, Ghebremedhin E, Rub U, et al. Stages in the development of Parkinson’s disease-related pathology[J]. Cell Tissue Res, 2004, 318: 121.
[10] Eskow JK, Angoa-Perez M, Kuhn DM, et al. Potential mechanisms underlying anxiety and depression in Parkinson’s disease: consequences of L-DOPA treatment[J]. Neurosci Biobehav Rev, 2011, 35: 556.
[11] Dissanayaka NN, White E, O’sullivan JD, et al. The clinical spectrum of anxiety in Parkinson’s disease[J]. Mov Disord, 2014, 29: 967.
[12] Carod-Artal FJ, Ziomkowski S, Mourao Mesquita H, et al. Anxiety and depression: main determinants of health-related quality of life in Brazilian patients with Parkinson’s disease[J].Parkinsonism Relat Disord, 2008, 14: 102.
[13] 劉卓,孫莉,黃曦妍. 帕金森病伴發(fā)焦慮與運(yùn)動(dòng)癥狀及非運(yùn)動(dòng)癥狀關(guān)系的研究[J]. 中華臨床醫(yī)師雜志,2012, 2: 288.
[14] Qureshi SU, Amspoker AB, Calleo JS, et al. Anxiety disorders, physical illnesses, and health care utilization in older male veterans with Parkinson disease and comorbid depression[J]. J Geriatric Psychiatry Neurol, 2012, 25, 233.
[15] Maricle RA, Nutt JG, Valentine RJ, et al. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson’s disease: a double-blind, placebo-controlled study[J]. Neurology, 1995, 45: 1757.
[16] 劉惠苗,李東,仇福成,等. 情緒對(duì)輕中度帕金森病患者認(rèn)知功能的影響[J]. 中國(guó)現(xiàn)代神經(jīng)疾病雜志, 2016, 2: 92.
[17] Fonoff FC, Fonoff ET, Barbosa ER, et al. Correlation between impulsivity and executive function in patients with Parkinson disease experiencingdepression and anxiety symptoms[J]. J Geriatr Psychiatry Neurol, 2015, 28: 49.
[18] Ahlskog JE, Muenter MD. Frequency of levodoparelated dyskinesias and motor fluctuations as estimated from the cumulative literature[J]. Mov Disord, 2001, 16: 448.
[19] Bjornestad A, Forsaa EB, Pedersen KF, et al. Risk and course of motor complications in a population-based incident parkinson’s disease cohort[J]. Park Rel Disord, 2016, 22: 48.
[20] Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of Parkinson’s diseaseon the quality of life[J]. Mov Disord, 2005, 20: 224.
[21] Richard IH, Frank S, McDermott MP, et al. The ups and downs of Parkinson disease. A prospective study of mood andanxiety fluctuations[J]. Cogn Behav Neurol, 2004, 17: 201.
[22] Marsh L. Anxiety disorders in Parkinson’s disease[J]. Inter Rev Psy, 2000, 12: 307.
[23] Ghielen I, van den Heuvel OA, de Goede CJT, et al. BEWARE: Body awareness training in the treatment of wearing-off related anxiety inpatients with Parkinson’s disease: study protocol for a randomized controlled trial[J]. Trials, 2015, 16: 283.
[24] Leentjens AFG, Dujardin K, Marsh L, et al. Anxiety and motor fluctuations in Parkinson’s disease: a cross-sectionalobservational study[J]. Park Rel Disord, 2012, 18: 1084.
[25] Starkstein SE, Robinson RG, Leiguarda R, et al. Anxiety and depression in Parkinson’s disease[J]. Behav Neurol, 1993, 6: 151.
[26] Chen JJ. Anxiety, depression, and psychosis in Parkinson’s disease: unmet needsand treatment challenges[J]. Neurol Clin, 2004, 22: S63.
InvestigationontherelationshipbetweenanxietyandthemotorcomplicationsinpatientswithParkinson’sdisease
WANGDa-li,SUNZheng-qin,DUNChang-ping,etal.
DepartmentofNeurology,NorthChinaUniversityofScienceandTechnologyAffiliatedHospital,Tangshan063000,China
ObjectiveTo explore the relationships between anxiety and the motor complication in patients with Parkinson’s disease (PD).MethodsMedical histories of 82 PD patients were collected. The Hamilton anxiety rating scale 14 item version (HAMA14), Hamilton depression rating scale 24 item version (HAMD24), Montreal cognitive assessment scale (MoCA), unified PD rating scale Ⅲ(UPDRS Ⅲ), unified PD rating scale Ⅳ (UPDRS Ⅳ) and Hoehn-Yahr stage in patients with PD were evaluated. The relationship between anxiety and motor complications was analyzed.ResultsAmong 82 patients, 47.56% were with anxiety, 43.90% were with motor complications. Compared with non-anxiety group, the incidence of motor complications and “on-off” phenomenon, HAMD24score, UPDRS Ⅲ score and Hoehn-Yahr stage were significantly higher, the course of disease was significantly longer, while the MoCA score was significantly lower in anxiety group (allP<0.05). Multivariate regression analysis showed that HAMD24score, Hoehn-Yahr stage were positively correlated with the HAMA14score (allP<0.05). Multifactorial Logistic regression analysis showed that the Hoehn-Yahr stage was the independent risk factor of exacerbation of motor complications (OR=2.462,P<0.05).ConclusionsThe incidence of motor complications in anxiety patients with PD is high, and it is prone to develop “on-off”phenomenon. The higher the depression score, the more severe the disease, the oftener anxiety develop.
Parkinson’s disease;anxiety;motor complications
R742.5
A
1004-1648(2017)05-0337-04
河北省衛(wèi)生廳醫(yī)學(xué)科學(xué)研究課題 (20130281)
063000唐山,華北理工大學(xué)附屬醫(yī)院神經(jīng)內(nèi)二科(王大力,孫正芹);河北醫(yī)科大學(xué)第一醫(yī)院神經(jīng)內(nèi)二科(敦昌平,顧平)
顧平
2016-10-07
2016-11-02)